key: cord-0724101-wyszsvuo
authors: Becker, Katrin Anne; Carpinteiro, Alexander; Hoffmann, Markus; Pöhlmann, Stefan; Kornhuber, Johannes; Gulbins, Erich
title: Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
date: 2021-02-03
journal: STAR Protoc
DOI: 10.1016/j.xpro.2021.100356
sha: 2cd92c7a93e7dbfeef31625e6b1c088793eec692
doc_id: 724101
cord_uid: wyszsvuo

This protocol enables the testing of drugs against infection of epithelial cells with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), using pseudo-typed replication deficient vesicular stomatitis virus particles (pp-VSV) presenting the SARS-CoV-2 spike protein. After treating human volunteers with amitriptyline, an approved antidepressant and inhibitor of the acid sphingomyelinase, freshly isolated nasal epithelial cells were infected ex vivo and infection levels were quantified. This protocol offers the possibility to rapidly test the efficacy of potential drugs in the fight against COVID-19.

Before You Begin The following protocols are described:

• Preparation and storage of pseudo-typed VSV particles presenting SARS-CoV-2 spike • Treatment of healthy volunteers • Isolation of nasal epithelial cells • Ex vivo treatment of nasal epithelial cells • Infection of freshly isolated nasal epithelial cells with SARS-CoV-2 spike pseudo-typed particles • Acid sphingomyelinase (Asm) activity assay to check for inhibition of Asm by amitriptyline • Quantification of ceramide CRITICAL: When planning the experiments, it is mandatory to get an approval of the local ethics committee for treating human volunteers with experimental drugs and nasal epithelial cell isolation and a written informed consent of the volunteers. NOTE: We used amitriptyline in our studies [Carpinteiro et al., 2020] . Amitriptyline is approved for human use for depression by the European Medicines Agency (EMA) and Food and Drug Administration (FDA). Experience has been available for decades; amitriptyline is a well-tolerated drug if the dosage recommendations are followed and the contraindications are observed. The special legal requirements for the use of drugs in humans must be observed. NOTE: For both assays, to determine Asm activity and quantify ceramide, radiolabeled biomolecules are used. Working with radioactivity requires special laboratories and a permission to use radionucleotides. NOTE: Before you start with the experiments, make sure that all media and buffers are prepared. Media should be stored at 4°C and warmed up to 37°C before use. Buffers are stored at 4°C if not indicated otherwise. NOTE: A few buffers are mixed directly before use as indicated below. Freshly isolated human nasal epithelial cells are directly infected. NOTE: All experiments with cells (cultured and freshly isolated primary cells) are performed under sterile conditions using a standard flow bench, and cells are incubated in a standard tissue culture incubator at 37°C with 5% CO 2 . NOTE: Samples to determine the acid sphingomyelinase activity and ceramide amount can be shockfrozen and stored at -80°C until the day when the assays are performed. NOTE: For all experimental procedures, we use Millipore water if not indicated otherwise. NOTE: The room temperature in our laboratories is 22°C. Even if the protocol below states 22°C instead of the phrase room temperature, these steps can be performed at 19-25°C as well.

Timing: 10-24 days NOTE: Working with SARS-CoV-2 pseudo-typed VSV particles requires laboratories equipped for biosafety level 2. NOTE: Steps 1 to 3 are preparatory steps that are not necessarily to be done every time you prepare pseudotypes.

1. Preparation of VSV*∆G-FLuc and VSV-G stocks [Timing: 3 days] a. Start new BHK-21(G43) cell culture. These cells express VSV-G protein if induced by mifepristone. b. Add VSV*∆G-FLuc stock to produce new VSV*∆G-FLuc or add VSV-G stock to prepare new VSV-G stock. CRITICAL: Both assays for testing the efficacy of amitriptyline to inhibit the acid sphingomyelinase, the Asm activity assay, and the quantitative determination of ceramide require radiolabeled biomolecules. Working with radioactivity requires special laboratories and a permission to work with radionucleotides.

a. The Asm assay can also be performed with fluorescence labeled sphingomyelin (e.g. BODIPY™ FL C 12 -Sphingomyelin; ThermoFisher Scientific; Cat# D7711). b. Ceramide quantification can be performed by mass spectroscopy, alternatively. c. Viral VSV-∆G-FLuc and VSV-G stocks as well as the antibody against VSV-G are commercial available from Kerafast. When using this material, you can directly begin with step 26 of the detailed protocol below. All these alternatives weren't used in our studies and are not described within this protocol.

Step-by-Step Method Details Preparation of pp-VSV-SARS-CoV-2 spike pseudo-typed viral particles

Pseudo-typed viral particles are based on a replication-restricted vesicular stomatitis virus (VSV) that codes for an enhanced green fluorescent protein (eGFP) and firefly luciferase (FLuc) instead of the parental VSV glycoprotein (VSV-G), VSV*ΔG-FLuc [Berger Rentsch & Zimmer, 2011] . Due to the inability of VSV*ΔG-FLuc to express VSV-G, this virus is unable to produce infectious progeny virions in the absence of in trans expression of VSV-G (or another suitable viral surface glycoprotein). Therefore, pseudo-typed VSV particles that harbor viral surface glycoproteins allow for a single infectious cell entry event into target cells and are thus safe surrogate vectors for studying cell entry of highly pathogenic viruses without the need to work with the authentic virus. Pseudo-typing of VSV*ΔG-FLuc was performed according to a previously published protocol add fresh medium without anti-VSV-G antibodies instead) incubate overnight (16-18 h) at 37°C with 5% CO 2 in a standard tissue incubator. 32. Collect supernatant, remove cellular debris by centrifugation at 2,000 x g for 10 min and transfer clarified supernatants into fresh tubes. 33. Use supernatants either directly for transduction of target cells or store supernatants at -80°C.

The acid sphingomyelinase (Asm)/ceramide system plays an important role in many bacterial and viral infections [Grassmé et al., 2003; Grassmé et al., 2005] . Asm catalyzes the hydrolysis of sphingomyelin to phosphorylcholine and ceramide. Many antidepressants functionally inhibit the Asm activity by displacing the enzyme from lysosomal membranes and thereby inducing Asm degradation [Hurwitz et al. 1994 ]. Previously, we have shown that amitriptyline, an approved antidepressant used in clinical routine and a functional inhibitor of the acid sphingomyelinase (FIASMA) [Albouz et al., 1981; Hurwitz et al., 1994; Kornhuber et al., 2008] , prevents infection with pseudo-typed replication deficient vesicular stomatitis virus particles presenting the SARS-CoV-2 spike protein (pp-VSV-SARS-CoV-2 spike) Carpinteiro et. al., 2020] .

Timing: 0.5 h

Human nasal epithelial cells are obtained from healthy, adult volunteers. We didn't observe any differences in infection between cells isolated from women or men. Therefore, isolation from both genders is feasible.

The first epithelial cell isolation should be performed before the oral administration of the drug, amitriptyline in the present study. 38. Pipette the cell suspension up and down once to mix the cells and then split the volume of each sample into identical aliquots (see figure 1 ) and transfer into a new microcentrifugation tube. Prepare aliquots as later needed. 39. Cells are pelleted by centrifugation (22°C, 830 x g) for 10 min and the supernatant is discarded. 40. For cellular infection continue with step 43 directly. For amitriptyline treatment ex vivo continue with step 50. Cells of another aliquot can be directly shock-frozen and stored at -80°C for Asm activity assay or continue immediately with step 52/56. Alternatively, cells of this aliquot can be used to determine ceramide amounts. To this end, continue with step 70 directly or shock-freeze cells and store at -80°C. Pause Point: Samples to determine Asm activity and ceramide can be shock-frozen and stored at -80°C.

Drug treatment of the volunteers 41. Directly after nasal cell isolation, human volunteers take amitriptyline orally (0.5 mg/kg). NOTE: Amitriptyline is approved for human use for depression by the European Medicines Agency (EMA) and Food and Drug Administration (FDA). Amitriptyline is a well-tolerated drug if the dosage recommendations are followed and the contraindications are observed. The special legal requirements for the use of drugs in humans must be observed. 42. 1.5 and 24 h after medication intake, isolation of nasal epithelial cells is repeated, identical to steps 35-40. NOTE: It is recommended to use the opposite nasal cavity for each successive epithelial cell collection to equalize the conditions.

Timing: 0.5-25 h 43. Cells of two aliquots are resuspended in 100 µL prewarmed MEM/10% FCS, containing pp-VSV-SARS-CoV-2 spike (infected sample) and transferred into one well of a 96-well plate each. 44. Cells are incubated for30 (to determine Asm activity and ceramide amounts) or 60 min (to determine infection rates) at 37°C. 45. For determination of Asm activity after infection, cells are transferred into a micro tube, centrifuged, and washed once with H/S buffer as above. Discard supernatant and directly continue with section Acid sphingomyelinase activity (step 52/56) or shock-freeze the cells (without buffer) and store them at -80°C until the assay is performed. Alternatively, cells can be used to perform ceramide determination. In this case, continue with step 70 or freeze cells. Pause Point: Samples to determine Asm activity or ceramide can be shock-frozen and stored at -80°C. 46. Another aliquot of cells is also transferred into a micro tube, centrifuged and washed once.

Resuspend cells in 100 µL fresh MEM/10% FCS and culture them for 24 h to allow expression of the enhanced green fluorescence protein (eGFP) encoded by the particles.

47. Next day, transfer cells into a micro tube, spin down cells at 830 x g for 10 min, remove medium and resuspend cells in 20 µL H/S. 48. Pipet an aliquot of 10 µL onto a glass slide, cover with a cover slip and immediately visualize the cells on a fluorescence microscope. 49. Infection is determined by expression of eGFP. To this end, slides are analyzed with a confocal microscope (we are using Leica TCS SL or Leica TCS SP5) using a 40x lens and an adequate software tool (e.g. Leica LCS software). At least 500 cells have to be counted for positive and negative eGFP expression in randomly chosen microscopic fields. Number of green fluorescent cells is set in relation to the total cells counted.

To compare efficacy of amitriptyline in vitro, one aliquot of freshly isolated nasal epithelial cells from untreated volunteers is treated with amitriptyline ex vivo. Amitriptyline (Sigma-Aldrich) should be freshly prepared as 10 µM solution in 0.9% NaCl.

50. Cells of one aliquot are resuspended in 100 µL of a 10 µM amitriptyline solution and transferred into one well of a 96-well plate. Incubate for 60 min at 37°C in an incubator. 51. After incubation, cells are centrifuged as above, supernatant is discarded, and cells are resuspended in 100 µL prewarmed MEM/10% FCS, containing pp-VSV-SARS-CoV-2 spike.

Check for the functional inhibition of the acid sphingomyelinase by amitriptyline

The antidepressant amitriptyline is a functional inhibitor of the enzyme acid sphingomyelinase (Asm). Asm catalyzes the degradation of sphingomyelin to phosphorylcholine and ceramide and plays a crucial role in many bacterial and viral infections, contributing to cellular entry of pathogens. We have previously shown that oral medication with amitriptyline by healthy volunteers inhibits the pseudoinfection of freshly isolated nasal epithelial cells with pseudo-typed VSV particles presenting SARS-CoV-2 spike on their surface [Carpinteiro et al., 2020] . Function of amitriptyline in vivo and ex vivo can be checked by using two different assays. The first assay determines the Asm activity by the use of an [ 14 C]labeled sphingomyelin, the substrate of the enzyme. The second assay determines one product of Asm reaction, intracellular ceramide amount, quantitatively.

Timing: 2-3 h NOTE: Work on ice if not indicated otherwise. Cell samples to determine Asm activity can be directly used or shock-frozen and stored at -80°C until the day of the assay. Centrifuge freshly prepared cell samples and discard the supernatant. Shockfrozen cell pellets should be quickly thawed at 37°C using a thermo shaker (see step 55).

As the substrate, radiolabeled [ 14 C]sphingomyelin is used. Assay readout is the release of hydrophilic [ 14 C]phosphorylcholine, separated by phase extraction from the lipophilic substrate. Working with radionucleotides requires special laboratories and the permission for handling radioactivity.

52. Place 270 µL pre-cooled Asm dilution buffer into a new micro tube for each sample to be analyzed. 53. Remove [ 14 C]sphingomyelin from the freezer and pipette 0.1 µL [ 14 C]sphingomyelin, corresponding to 0.05 µCi, for each sample into one new micro tube. NOTE: Always prepare sphingomyelin for the number of samples to be analyzed plus one (e.g. 20 samples means 2.1 µL ((20+1)*0.1 µL), corresponding to 1.05 µCi). 54. Dry the sphingomyelin resolved in organic solvent in a vacuum concentrator for 10 min (larger volumes may take longer). 55. Meanwhile, transfer frozen samples into a thermo shaker and thaw them quickly at 37°C. 56. Add 200 µL pre-cooled Asm lysis buffer to each sample and place samples on ice for 5 min. 57. In the meantime, continue with the dried substrate for the assay. Add 30 µL Asm assay buffer per original 0.1 µL to dried sphingomyelin (e.g. 20 samples means 630 µL assay buffer ([20+1]×30 µL)) and sonicate in a sonication bath for 10 min to promote micelle formation. 58. Add 30 µL of lysed sample to pre-pipetted Asm dilution buffer to dilute NP40 concentration to 0.2% (final volume, V end = 300 µL). 59. Add 30 µL of sonicated [ 14 C]sphingomyelin (in Asm assay buffer) to each sample (V end = 330 µL). NOTE: Sonicated sphingomyelin should not be vortexed or pipetted up and down before aliquoting. 60. Vortex each sample and transfer the tube into an 37°C pre-warmed thermo shaker and incubate for 30 -60 min at 300 rpm horizontal shaking and 37°C. 61. Enzymatic reaction is terminated by adding 800 µL of freshly mixed lipid extraction mixture (CHCl 3 :CH 3 OH, 2:1, v/v). 62. Vortex each sample for 30 seconds. 63. Separate hydrophilic and hydrophobic phases by centrifugation at maximum speed in a micro centrifuge for 5 min. 64. In the meantime pipette 4 mL scintillation fluid into a scintillation vial for each sample. 65. The radioactive labeled product is [ 14 C]phosphorylcholine that is in the upper hydrophilic phase and therefore can be separated from the lipophilic substrate [ 14 C]sphingomyelin which is in the lower lipid phase. Take an aliquot of the upper phase by pipetting twice 125 µL of the upper phase into prepared scintillation vials. NOTE: This must be done very carefully without mixing the two phases or taking anything from the lower or intermediate phase. 66. Positive control: Add 20 µL of [ 14 C]sphingomyelin in Asm assay buffer (see step 2) to 4 mL scintillation liquid. Negative control: One scintillation vial with scintillation fluid, but without a sample. 67. Vortex each scintillation vial for 10 seconds and wait for 10 min before analyzing them in a scintillation counter. 68. Calculation of Asm activity:

Using the specific activity of [ 14 C]sphingomyelin, the counts of each sample are converted into the amount of product (moles). For calculation of the specific Asm activity (amount of product per time and amount of protein), the time of assay (30 -60 min) and the amount of protein used has to be considered and specific enzyme activity is expressed as mol/mg/h. Protein determination can be performed with a commercial kit compared with a calibration protein series. OPTIONAL: You can use the remaining lysed sample (in Asm lysis buffer; step 59; 170 µL) for ceramide determination. This approach saves sample, but requires a certain routine with methodology. Samples should be directly used or shock-frozen again. Pause Point: The rest of the samples can be shock-frozen and stored at -80°C and used for quantitative ceramide determination later (step 70).

Timing: 6-12 h NOTE: Cell samples to determine ceramide can be directly used or shock-frozen and stored at -80°C until the day of ceramide assay. Centrifuge freshly prepared cell samples and discard the supernatant.

Shock-frozen cell pellets should be quickly thawed at 37°C using a thermo shaker.

To determine ceramide, [ 32 P] γATP is used to phosphorylate endogenous ceramide of the cell samples.

Within the 60-minute assay period the entire endogenous ceramide present in the samples is converted to radioactive ceramide-1-phosphate (and a fraction of non-radioactive ceramide). Readout is phosphorylated ceramide that can be quantified with an imager after thin-layer chromatography (TLC) and in comparison to standard ceramide series. Since [ 32 P] has a half-life of 28 days, current radioactivity has to be calculated and considered when pipetting the master kinase assay mix. Working with radionucleotides requires special laboratories and the permission for handling radioactivity.

69. Prepare a TLC chamber with 100 mL of freshly prepared TLC running buffer, consisting of 

In contrast, only drugs inhibiting the acid sphingomyelinase should result in reduced Asm activity and reduced ceramide levels.

The findings generated by these experimental systems do not necessarily reflect the clinical situation in COVID-19 patients. Clinical studies are required to define the use of the potential medications tested by other researchers. In fact, the potential use of antidepressants for the treatment of COVID-19 patients [Carpinteiro et al., 2020] was strongly supported by a recently pre-printed retrospective multicenter study in France demonstrating reduced risk of intubation and death of COVID-19 patients upon the use of antidepressants [Hoertel et al., 2020] . Potential Solution:

Repeat the preparation of transfection mixture. It may be helpful to add the 2xHBS buffer dropwise while gently and constantly vortexing. The transfection mixture must be clear prior to its addition onto the cells. A clear solution contains small Ca 3 (PO 4 ) 2 precipitates which is a prerequisite for effective transfection. A cloudy transfection mixture indicates large CaPO 4 precipitates and will result in low transfection efficacy.

Nasal epithelial cell isolation:

Insufficient numbers of cells to analyze (steps 36, 37).

Either you have isolated insufficient numbers of cells (step 36) or the isolated nasal epithelial cells are not well released from the brush (37). Repeat the isolation procedure and make sure that the brush is inserted up to 2 cm. Sometimes it may helpful to press a finger onto that region of the nose where you want to place the brush. Also make sure that all cells are released from the brush by carefully rotating the brush at the inner side of the conical tube.

Asm activity assay:

Scintillation counts are not detectable (step 67).

The only possible explanation, besides a defect of your scintillation counter, is omitting to add the radiolabeled sphingomyelin. Repeat the complete assay. Potential Solution:

This can happen when the samples were wiped with a dry paper towel before scintillation measurement leading to electrical charging. Let the samples stand for a while and repeat measurement.

Another explanation is the contamination of samples (upper, hydrophilic phase) with varying amounts of the lipophilic phase. When pipetting the upper phase, be very careful not to mix the phases. If you have any doubts concerning contamination or mixing of the phases, centrifuge the sample tubes once again. Start over again with step 63.

Quantitative ceramide determinations:

Either no or weak signals are detected on the TLC plates (step 87).

Potential Solution:

Calculation of aged [ 32 P] γATP is wrong. Calculate the amount of 5 µCi [ 32 P] γATP once again and repeat the complete assay with shock-frozen samples.

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katrin Anne Becker (katrin.anne.becker@uni-due.de).

Request for material and reagents to generate the rhabdoviral vectors used in this study can be directed to Markus Hoffmann (mhoffmann@dpz.eu) and Stefan Pöhlmann (spoehlmann@dpz.eu). It will be made available upon installment of a material transfer agreement (MTA).

No new datasets or codes were generated in the preparation of this manuscript.

Please note that several reagents are available in similar designs from other manufacturers. In this manuscript, we describe the reagents that we used. Alternative reagents may work in the same way.

J o u r n a l P r e -p r o o f

One day prior to infection, seed BHK-21(G43) cells into T-75 flask in 10 mL medium (10% FBS). Grow cells at 37°C with 5% CO 2 in a standard tissue incubator

Once cells reach 75% confluence (typically achieved at 24 h post seeding), remove old culture medium and add new culture medium containing 10 -8 M mifepristone and incubate for 6 h

Remove medium and immediately add 8 mL DMEM containing diluted (1:1,000) VSV*ΔG-FLuc (or alternatively VSV-G is used as positive control) stock

Remove medium, wash 2 -3 times gently with PBS

Add 20 mL DMEM (high glucose) & 5% FCS supplemented with 10 -8 M mifepristone and incubate for 16-24 h at 37°C with 5 % CO 2 (until most of the cells are rounded and detached)

Collect supernatant, centrifuge to pellet cellular debris for 10 min at 2,000 x g at 22°C

Prepare aliquots of 1 mL in cryo vials, flash-freeze samples and store at -80°C

Grow cells at 37°C with 5% CO 2 in a standard tissue incubator. Cells should reach 75% confluence (typically achieved at 24 h post seeding) for infection

On the day of infection, prepare 10-fold serial dilutions of VSV*ΔG-FLuc (or alternatively VSV-G) stock by mixing of 900 µL culture medium with 100 µL of VSV*ΔG-FLuc (or alternatively VSV-G) stock (or previous dilution). Remove old culture medium and inoculate serially diluted VSV*ΔG-FLuc(VSV-G) onto cells

Counting is typically done by eye but can also be performed using an automated fluorescence reader (e.g., Bioreader-7000-F from Bio-Sys). Calculate titer of VSV*ΔG-FLuc (VSV-G) stocks according to the following formula: Titer [ffu/mL] = average no. of eGFP-positive cells (of technical triplicates) x reciprocal serial dilution factor (dilution in which eGFP-positive cells were counted) x inoculum dilution factor

Grow cells at 37°C with 5% CO 2 in a standard tissue incubator. Cell culture flasks should be kept in an upright position in the incubator in order to allow addition of cell culture medium volumes >20 ml

When the cell count reaches 1 x 10 6 cells/mL, split cells 1:4 in order to obtain 4x T-75 flasks of CRL-2700 cells

Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures

A Versicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon

Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts

Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms

Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes

Association between SSRI antidepressant use and reduced risk of intubation or death in coronavirus disease 2019: a multicenter retrospective observational study

The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts

Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization

Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model

The study was supported by Deutsche Forschungsgemeinschaft, Germany, grants Gu-335-35/1 and GU-335-38/1 to E.G. and Federal Ministery of Science (BMBF), RAPID Consortium grant 01KI1723D to S.P.. 

The authors declare no competing financial interests.